{"name":"Veru Inc.","slug":"veru","ticker":"VERU","exchange":"NASDAQ","domain":"verupharma.com","description":"Veru Inc. is a biopharmaceutical company focused on urology and oncology. The company's top drugs include duvelisib, a kinase inhibitor for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia, and veruviq, a selective alpha-1 adrenergic receptor antagonist for the treatment of benign prostatic hyperplasia. Veru Inc. is a relatively small player in the biotech industry, but its pipeline and existing products have potential for growth.","hq":"Miami, FL","founded":0,"employees":"","ceo":"Mitchell Steiner","sector":"Biotech — Urology / Oncology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$95M","metrics":{"revenue":16296958,"revenueGrowth":-58.6,"grossMargin":0,"rdSpend":15588185,"netIncome":-22726279,"cash":29835719,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2023"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"duvelisib patent cliff ($0.0B at risk)","drug":"duvelisib","type":"patent_expiry","sentiment":"negative"},{"date":"2028-06-01","label":"veruviq patent cliff ($0.0B at risk)","drug":"veruviq","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Enzalutamide, Abiraterone","genericName":"Enzalutamide, Abiraterone","slug":"enzalutamide-abiraterone","indication":"Metastatic castration-resistant prostate cancer (mCRPC)","status":"phase_3"}]}],"pipeline":[{"name":"Enzalutamide, Abiraterone","genericName":"Enzalutamide, Abiraterone","slug":"enzalutamide-abiraterone","phase":"phase_3","mechanism":"This combination of an androgen receptor antagonist (enzalutamide) and a CYP17A1 inhibitor (abiraterone) blocks testosterone production and androgen signaling to treat hormone-sensitive prostate cancer.","indications":["Metastatic castration-resistant prostate cancer (mCRPC)","Metastatic hormone-sensitive prostate cancer (mHSPC)"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Veru Inc. Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Veru Inc. reported its financial results for the fourth quarter and full year 2023, with revenue of $13.4 million and a net loss of $34.1 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Veru Inc. Announces Collaboration with the University of California, Los Angeles (UCLA) to Develop Novel Therapies for Prostate Cancer","summary":"Veru Inc. announced a collaboration with UCLA to develop novel therapies for prostate cancer, with a focus on identifying new targets for treatment.","drugName":"","sentiment":"positive"},{"date":"2023-08-02","type":"regulatory","headline":"Veru Inc. Receives FDA Approval for Duvelisib in Combination with Rituximab for the Treatment of Relapsed or Refractory Follicular Lymphoma","summary":"Veru Inc. received FDA approval for duvelisib in combination with rituximab for the treatment of relapsed or refractory follicular lymphoma.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5YZ0hqVE9kRGd6bGN1MlVXWUVLY2RUZ3hDV2ZJWEJHcXR5T3BvZE1OWmgzdFd0UV92SVcyQ0tpd1BkQU1MOFc5NDJROEUtTnN5Mm1YbnNueXFBQWUwa3FHa1Y5SHE2Z3I2TXdMVHN3?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Veru (VERU) - Stock Titan","headline":"If You Invested $1,000 in Veru (VERU)","sentiment":"neutral"},{"date":"2026-03-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-02-11","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2026-02-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxPb3BVYVVSNnRlRFpQRE5raEJ0VnJoanBVd0ZVdDlNaDhPLW5CVDdqdERVUmNDbTBpRjZnRjJyNW10dFVaWmliMjIyZFV4Z2RaWm0yQXpCTmZGd2dHbUQ4SkkycU9OWlVtYko4SnJ0ejZDRk5ZYVBUVkkzclRtYVd1SUVuZFVkRHpmNjFDZ0hnRVZoSk1VdDVtNzBsV1lYcFFpRFdkWXY5NTF1WUw2UjJURHFkOHExekJnNU11OUNfc3VyVDRXRjFDSDAwLTg3MW45NjJDeklEOS1iZHZkbDhuSg?oc=5","date":"2026-02-04","type":"earnings","source":"GlobeNewswire","summary":"Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th - GlobeNewswire","headline":"Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th","sentiment":"neutral"},{"date":"2025-12-17","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: FORM 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2025-12-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-10-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-08","type":"pipeline","source":"simplywall.st","summary":"Veru Inc.'s (NASDAQ:VERU) Share Price Boosted 29% But Its Business Prospects Need A Lift Too - simplywall.st","headline":"Veru Inc.'s (NASDAQ:VERU) Share Price Boosted 29% But Its Business Prospects Need A Lift Too","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-23","type":"regulatory","source":"GlobeNewswire","summary":"Veru Announces Successful FDA Meeting Providing Regulatory - GlobeNewswire","headline":"Veru Announces Successful FDA Meeting Providing Regulatory","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE5JZUdacWljSEEwMVhrSnBVTDItN3FkdDdMZ2EwTjhYRE5sN2hJUFJDd2hoVUM3dkh3bnpFUFJVbTFqSmJCT0dTN1FUTG1jZnk3UzA5dHNidERuZXJaMTlBcl9UeHphbkN4UEY0RQ?oc=5","date":"2025-08-15","type":"deal","source":"Zacks Investment Research","summary":"Should I buy Veru (VERU) - Zacks Investment Research","headline":"Should I buy Veru (VERU)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPWDl5VDRSMTg5VVJucWNIYnZIckgwZWpYU0FGdFFSVWhTeWkxdThQUVl3T09OclFESElmWWRWVzczNHNDMG5HaUxiWnZpcC1xOFhLT1paUE1vRW9VaUtzVjZlS21YclQ4cDhiTFgtWXhnMDhzUDlwc3FURnJWQWo5LXNsMGVoU011R1B3MXFR?oc=5","date":"2025-08-11","type":"trial","source":"Yahoo Finance","summary":"Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study - Yahoo Finance","headline":"Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Followi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOWmlKdXRSWjU1SjJlTzh4WEZiNWhhd2VZU28tZFBaZGdhNW1hVnFRWjFtbjgxMDl6cnc5dnhiQ3U5Y0hrWVVQblJmX0ZCTWNTODRMSW83VkstMmpNcWtaOTZJblBKSXJHWXN4em9FMnhnNzEtLWZfcC1qSGo5bDRDbFpqVzF6bU5US3RpYkFKS1lpZUU?oc=5","date":"2025-08-11","type":"pipeline","source":"Yahoo Finance","summary":"Laxxon Medical Announces Successful Product Development Milestone with Novel Oral Modified-Release Formulation of Veru’s Enobosarm, Utilizing Laxxon’s SPID®-Technology - Yahoo Finance","headline":"Laxxon Medical Announces Successful Product Development Milestone with Novel Oral Modified-Release Formulation of Veru’s","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxObS1mTmQ5WEtHZ29haG5uOFdrSHFBa05iMnNISl8zNkdhZFpvSmwybVNyNzZPVUVnbjRKRmxhdzVTTWxVWTZBU0ptR084ZkpiZHJUYjhibzVnVW9MSUtpOGJoeXg4UU5lRHZSUFc3QXItSG5kb0JTUk9jSEV4d1V0Q3puMzVkTkg4QlRJc3FFOGU?oc=5","date":"2025-05-28","type":"trial","source":"BioPharma Dive","summary":"Muscle-sparing obesity drug safe for Phase 3 trial, Veru says - BioPharma Dive","headline":"Muscle-sparing obesity drug safe for Phase 3 trial, Veru says","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOVHhNc21LZkVOSjFIWFFmZ1FfUkQ0UHdrcjFlb1h2Z2hzdTVQNUtoM1p5b2ZGdEpLaGp2SEE2ckp2dEd6RVVUTGFrMGZDa3dKSnNZU2tqUEVlUXRpTFBqdnFtTG9FUmRmNWVKLWJYaW9RS0VPQU16N3NKWnpzTFN6XzZDSllGZmVIN1BzYmlxdU1CSnFES2xrQ19BZnZidw?oc=5","date":"2025-05-26","type":"pipeline","source":"Seeking Alpha","summary":"Veru: Saving Muscle Mass Amidst The GLP-1 Drug Boom - Seeking Alpha","headline":"Veru: Saving Muscle Mass Amidst The GLP-1 Drug Boom","sentiment":"neutral"}],"patents":[{"drugName":"veruviq","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":0},{"drugName":"duvelisib","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Johnson & Johnson","AstraZeneca","Bayer AG"],"therapeuticFocus":["Urology","Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":16296958,"revenuePeriod":"2023-09-30","revenueHistory":[{"value":16296958,"period":"2023-09-30"},{"value":39354352,"period":"2022-09-30"},{"value":39354352,"period":"2022-09-30"},{"value":61259528,"period":"2021-09-30"},{"value":61259528,"period":"2021-09-30"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":15588185,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-22726279,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":29835719,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}